Investors of Capricor Therapeutics Face Class Action Lawsuit After Stock Plummets
Investors in Capricor Therapeutics, Inc. are now faced with the fallout from a recent class action lawsuit that has emerged due to considerable losses experienced among shareholders.
The class action, initiated by Robbins LLP, encompasses all individuals and entities who acquired Capricor securities between December 17, 2025, and July 26, 2026. At the heart of the lawsuit lies the allegation that Capricor misled investors regarding the approval process of its leading product candidate, Deramiocel, a cell therapy designed to manage cardiac and skeletal muscle issues linked to Duchenne muscular dystrophy (DMD).
Background of Capricor Therapeutics and Deramiocel
Capricor Therapeutics specializes in developing innovative cell and exosome-based therapies for rare diseases. Among its most promising developments is Deramiocel, which aims to treat serious complications arising from DMD. The company submitted a Biologics License Application (BLA) for this therapy in late 2024. However, things took a turn when the FDA sent a Complete Response Letter in July 2025, indicating that Capricor had not met the standards concerning substantial evidence of effectiveness and requested further clinical data.
The lawsuit asserts that during the specified Class Period, Capricor made optimistic claims about Deramiocel's clinical results, while neglecting to disclose crucial information regarding modifications to the pre-defined statistical analysis plan (SAP) used for evaluating clinical trials of the product. This lack of transparency has sparked serious concerns among investors about the company's integrity.
Impact of FDA Disclosure on Investors
On July 27, 2026, fresh disclosures from the FDA relating to Deramiocel further exacerbated the situation. The agency revealed in its briefing documents that Capricor made changes to the previously agreed-upon SAP, which ultimately could favorably alter the clinical data. Importantly, these changes were neither presented to the FDA before the BLA was submitted nor had they been formally agreed upon, raising red flags over the credibility of the data presented to regulators.
In response to these alarming disclosures, Capricor's stock price plummeted by approximately 64% in one session, closing at $7.00 per share. This dissatisfied investors sparked further scrutiny into the company, especially with the subsequent news that the FDA advisory committee voted 9-3 against the efficacy of Deramiocel, causing stock values to further deteriorate, landing at $4.19 per share shortly after.
Who Is Affected and What Can They Do?
Individuals who acquired Capricor securities during the specified class period and have suffered losses are eligible to take part in this class action lawsuit. Robbins LLP will act on a contingency fee basis, meaning shareholders will not incur upfront costs for legal representation. The firm has encouraged those affected to come forward quickly, with the deadline for seeking appointment as lead plaintiff set for September 28, 2026.
“This case represents a critical moment for investors who trust in biotech innovation and the promises made by companies like Capricor,” states Brian J. Robbins, the founding partner of Robbins LLP. “Investors deserve accurate information regarding their investments, and we are dedicated to holding companies accountable.”
Conclusion
As the legal battle unfolds, the outcome may set a precedent for similar cases in the biotechnology field, shedding light on the responsibilities of companies to disclose truthful and comprehensive information regarding their products and business practices. Investors seeking further information can contact Robbins LLP or register through their website to stay updated about this case. The emphasis remains on ensuring that shareholders' rights are respected and that they achieve potential recovery from their investments.
The class action, initiated by Robbins LLP, encompasses all individuals and entities who acquired Capricor securities between December 17, 2025, and July 26, 2026. At the heart of the lawsuit lies the allegation that Capricor misled investors regarding the approval process of its leading product candidate, Deramiocel, a cell therapy designed to manage cardiac and skeletal muscle issues linked to Duchenne muscular dystrophy (DMD).
Background of Capricor Therapeutics and Deramiocel
Capricor Therapeutics specializes in developing innovative cell and exosome-based therapies for rare diseases. Among its most promising developments is Deramiocel, which aims to treat serious complications arising from DMD. The company submitted a Biologics License Application (BLA) for this therapy in late 2024. However, things took a turn when the FDA sent a Complete Response Letter in July 2025, indicating that Capricor had not met the standards concerning substantial evidence of effectiveness and requested further clinical data.
The lawsuit asserts that during the specified Class Period, Capricor made optimistic claims about Deramiocel's clinical results, while neglecting to disclose crucial information regarding modifications to the pre-defined statistical analysis plan (SAP) used for evaluating clinical trials of the product. This lack of transparency has sparked serious concerns among investors about the company's integrity.
Impact of FDA Disclosure on Investors
On July 27, 2026, fresh disclosures from the FDA relating to Deramiocel further exacerbated the situation. The agency revealed in its briefing documents that Capricor made changes to the previously agreed-upon SAP, which ultimately could favorably alter the clinical data. Importantly, these changes were neither presented to the FDA before the BLA was submitted nor had they been formally agreed upon, raising red flags over the credibility of the data presented to regulators.
In response to these alarming disclosures, Capricor's stock price plummeted by approximately 64% in one session, closing at $7.00 per share. This dissatisfied investors sparked further scrutiny into the company, especially with the subsequent news that the FDA advisory committee voted 9-3 against the efficacy of Deramiocel, causing stock values to further deteriorate, landing at $4.19 per share shortly after.
Who Is Affected and What Can They Do?
Individuals who acquired Capricor securities during the specified class period and have suffered losses are eligible to take part in this class action lawsuit. Robbins LLP will act on a contingency fee basis, meaning shareholders will not incur upfront costs for legal representation. The firm has encouraged those affected to come forward quickly, with the deadline for seeking appointment as lead plaintiff set for September 28, 2026.
“This case represents a critical moment for investors who trust in biotech innovation and the promises made by companies like Capricor,” states Brian J. Robbins, the founding partner of Robbins LLP. “Investors deserve accurate information regarding their investments, and we are dedicated to holding companies accountable.”
Conclusion
As the legal battle unfolds, the outcome may set a precedent for similar cases in the biotechnology field, shedding light on the responsibilities of companies to disclose truthful and comprehensive information regarding their products and business practices. Investors seeking further information can contact Robbins LLP or register through their website to stay updated about this case. The emphasis remains on ensuring that shareholders' rights are respected and that they achieve potential recovery from their investments.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.